Join Us

Pourquoi notre ICO n’est pas comme les autres ?

Une étude du Boston College a montré que 56% des startups qui lèvent de fonds en tokens (Initial Coin Offering) disparaissent au bout de 4 mois. Vous méritez beaucoup mieux. Plutôt que de lancer un projet sans consistance, Embleema travaille depuis 18 mois à réunir les facteurs clés du succès sur le long terme:

Voir l’étude

Un produit déjà disponible

PatientTruth, l’application décentralisée permet aux patients d’être propriétaires de leurs données, est déjà disponible.

Une équipe expérimentée

Une équipe de management qui a déjà occupé des postes à responsabilité dans la santé digitale et dans les données de santé. L’équipe bénéficie du soutien d’un board de responsables de très haut niveau dans la santé.

Une ICO bien préparée

Nous sommes conseillés par des institutions renommées, notamment le cabinet Fieldfischer, et travaillons en transparence avec les autorités.

Soutien clients

Embleema a déjà signé avec plusieurs laboratoires pharmaceutiques et associations de patients.

Contactez nous pour souscrire

L’opportunité des données en vie réelle de nouvelle génération

L’émérgence de la santé digitale…
Les solutions existantes: un processus de collecte de données en vie réelle manuel et fastidieux
Processus long et coûteux due au nombre d’intermédiaires
Données agrégées de basse résolution
Absence de trace d’audit et de consentement
Conditions de vente imposées par les intermédiaires
Données en vie réelle de nouvelle génération
Données en temps réelles sans intermédiaires grâce aux smarts contracts
Données de haute résolution au grain individuel
Consentement & traçabilité pour les patients
Les patients fixent leurs conditions de partage et vente

Une road-map pour désintermédier la recherche clinique

Après la mise en ligne de l’application décentralisée PatientTruth, Embleema construit une place de marché pour les données en vie réelle (RWE), afin de créer une relation plus équitable entre les patients et les chercheurs de l’industrie pharmaceutique, en leur permettant de choisir librement avec quelle étude partager leurs données. Le partage en temps réel de données au grain individuel permettra un meilleur suivi des nouveaux traitements en vie réelle, pour accélérer leur disponibilité auprès des patients.

Copier toutes vos données depuis Apple HealthKit

Choisir parmi une liste d’études cliniques

Être récompensée pour sa participation active

  • Copier toutes vos données depuis Apple HealthKit

  • Choisir parmi une liste d’études cliniques

  • Être récompensée pour sa participation active

L’Ecoystème Embleema
Nous offrirons aux tiers la possibilité de développer leurs propres applications pour les domaines thérapeutiques cibles

Modèle de Tokenomics

Informations d’investissement

Un maximum de 500 000 000 tokens RWE seront émis pour les opérations de la Blockchain Embleema Santé.

Allocation des tokens

48% - Paiement des détenteurs de données enregistrant leurs données de santé
Jusqu’à 30% pour les souscripteurs de la vente de tokens initiale
15% - Fondateurs d’Embleema et l’équipe élargie
7% - Marketing et le développement de la communauté

Utilisation des fonds

29% - Fourniture du service
25% - Vente et Marketing
19% - Développement produit
14% - Opérations et support
13% - Management
  • Vente privée

    Notre ventre privée a démarré (sur invitation). Merci de nous contacter
  • Vente publique

    Bientôt !

    Merci de rejoindre notre waitlist.

  • Type de Token

    RWD (Real World Data) token

    Le token RWD sera converti en token RWE (Real World Evidence) au lancement du réseau de deuxième génération Embleema selon une conversion 1:1.

  • Valeur initiale du token:

    0.1734 Euros
  • Protocol du token

    ERC-20
  • Montant maximum de la vente de Tokens

    150,000,000 RWD
  • Soft Cap

    15,000,000 RWD
  • Hard Cap

    150,000,000 RWD
  • Formes de paiement acceptées

    USD, Euros, ETH, BTC, BCH
Conditions de souscription

La vente de tokens n’est pas ouverte au citoyen et résidents des Etats-Unis, Chine, Canada, Nouvelle Zélande, Corée du Nord et tous les pays inclus dans la liste des pays non-coopératifs du TATF.

RWE Token Value ($)
    • 300k
    • 700k
    • 1Mn
    • 1,3Mn
    • 1,6Mn
    • 1k
    • 5k
    • 10k
    • 15k
    • 20k
    • 1
    • 2
    • 3
    • 4

    Milestones

    • Company
    • Product Barrier to entry and IP
    • Customers
    Développement produit
    2017
    Mai
    Création d’Embleema
    Juillet
    Prototype Embleema lancé
    2018
    Juillet 2018
    Lancement de la V 1.0: 1ère application patient décentralisée IP: Data Parser & smart contract d’autorisation
    Demande
    Octobre
    Pilot #1: Mucoviscidose
    4ème trimestre
    Souscription de tokens
    Novembre
    Pilot #2: FDA & Big Pharma
    Croissance
    2ème au 4ème trimestre
    Adaptation UX/UI avec les pilotes clients. IP: Système de gestion des portefeuilles
    2019
    Juillet
    V2.0. Place de marché décentralisée & applications IP: Smart contract pour les places de marché
    Expansion
    2ème semestre
    Lancement en France
    2020
    1er semestre
    Lancement en Chine
    2021
    1er trimestre
    V3: Parma, assurances et centre de soins deviennent mineurs, applications tiers sur la Blockchain Embleema
    4ème trimestre
    250 000 dossiers patients sur la place de marché
    2022
    1er trimestre
    V4: Analytics pour la gestion de la santé au niveau des populations
    4ème trimestre
    400 employés
    4ème trimestre
    700 000 dossiers patients sur la place de marché
    2023
    4ème trimestre
    1,6M dossiers patients sur la place de marché

    Équipe

    L’équipe d’Embleema cumule une expertise acquise dans l’industrie pharmaceutique, les données de santé, les objets connectés et les applications de santé, ainsi que la Blockchain, avec des experts ayant mené leurs carrières aux Etats-Unis, en Europe et en Asie-Pacifique.

    Core Team
    Robert Chu
    CEO

    Former CEO of IQVIA France & Asia & Global SVP of Technology Solutions

    Lire la bio
    Alexis Normand
    Head of Blockchain Consortium

    Former Head of B2B at Nokia

    Lire la bio
    Nicolas Schmidt
    Chief Product Officer

    Former Head of Healthcare Products at Nokia and Withings

    Lire la bio
    Nathalie Lambert
    Data Privacy Officer & Head of Partnerships
    Lire la bio
    Sophie Martineau
    VP of Sales
    Lire la bio
    Matthieu Vegreville
    Data Scientist
    Lire la bio
    Benjamin Apra
    Bioinformatics Engineer
    Lire la bio
    Yves Ordonneau
    Technical Implementation and Operations Director
    Lire la bio
    Zac Thomas
    Strategy Advisor
    Lire la bio
    Prashant Khambekar, PhD
    Chief Blockchain Development Executive

    SVP Blockchain Harbringer

    Lire la bio
    Vincent Galand
    Operations Manager

    Former Partnership and Business Development Manager at Ad Scientiam

    Lire la bio
    Atakan Seçkin
    User Experience Advisor

    Ex UX / UI designer at Google

    Lire la bio
    Munair Simpson
    Crypto Community - Asia

    Principal Advisor Usefulcoin. Contributor at CoinCentral and Coin Telegraph.

    Lire la bio
    Advisory Board
    Frederic Duchesne, Pharm.D.
    CEO of Pierre Fabre Pharmaceuticals

    Board Member of the European Federation of Pharmaceutical Industries and Associations

    Lire la bio
    Vahan Simonyan, PhD
    Chief Scientist - WHISE-Embleema Health Blockchain Consortium

    Former R&D Director of Bioinformatics at the Food and Drug Administration (FDA)

    Lire la bio
    Pr. John Halamka, MD
    Professor of Innovation at Harvard Medical School

    CIO at Beth Israel Deaconess, Chairman at New England Health Exchange Network (NEHEN)

    Lire la bio
    Adel Al-Saleh
    CEO of T-Systems and Board Member of Deutsche Telekom

    Member of the Board of Management at Deutsche Telekom

    Lire la bio
    Bernard Gilly, PhD
    CEO at GenSight Biologics & Chairman at iBionext
    Lire la bio
    Nathalie Grandfils
    Epidemiologist
    Lire la bio

    Questions fréquemment posées

    How do I check my RWD balance with myetherwallet.com?
        1- Go to https://www.myetherwallet.com


      Step 1 illustration

        2- Click on « View wallet info »


      Step 2 illustration

        3- In the list, you have to click on « Private Key »


      Step 3 illustration

        4- Enter the private key from the « Embleema Gift card » you received earlier


      Step 4 illustration

        5- Click on « unlock »

        6- Now your Ethereum wallet is open, you can access your private key and your balance.
        7- In order to see your RWD balance, click on « Show All Tokens »


      Step 7 illustration

        8- In this list, you have to click on the « Click to load » link next to « RWD »


      Step 8 illustration

        9- Wait 30 seconds and your balance will appear

        10- To close the wallet you just have to close the tab / windows of your web browser

    What is an ICO ?

    ICO stands for “Initial Coin Offering” and it is a means of raising capital through a crowdfunding campaign with the use of crypto-assets as investment. A digital asset, the coin or the token, is issued for a purpose and are sold to raise money for the said purpose. After the ICO process is done, the coins are traded on crypto-exchanges and market supply and demand decides on their fair pricing.

    What is the token price?

    The token price of the RWD token is $0.20

    Is there minimum to invest?

    During the presale phase, a minimum amount of 20,000 USD is required. During the public sale phase, the minimum amount required is 200 USD.

    Can I buy RWD with fiat or other cryptocurrencies?

    The RWD tokens can be bought using Euros (EUR), U.S. dollars (USD), bitcoins (BTC), bitcoin cash (BCH) and ethers (ETH)

    What wallet can I use to contribute?

    The RWD is an ERC-20 token, hence you will need an ERC-20 wallet on the Ethereum mainnet to receive your RWD tokens once you purchased them

    Does the purchasing of RWE tokens require me to go through a “Know Your Customer” (KYC) process?

    Yes, after you register to the whitelist, you will be asked to undergo a KYC (Know Your Customer) validation before being authorized to purchase RWD tokens.

    Is there a whitelist?

    Yes, a whitelist will be open before the public sale. Whitelisted potential subscribers to the RWD token will be subject to a KYC (Know Your Customer) validation before being authorized to purchase RWD tokens.

    What was the pre-sale discount and why did early investors get high bonus?

    The presale bonus is 30%. Presale subscribers are rewarded for being early and significant contributors to the funding of our project.

    What is the total token supply?

    The maximum total RWD token supply is 500,000,000 tokens.

    What is the maximum amount of tokens sold at the Founder’s token sale?

    The total token supply open to subscribers of the Founder’s token sale is 150,000,000 RWD tokens, which makes up 30% of the total amount of tokens.

    What are the Softcap and Hardcap?

    The softcap is 15,000,000 RWD tokens (2,000,000 USD), and the hardcap is 150,000,000 RWD tokens (20,000,000 USD).

    Will US residents be able to participate in the ICO?

    No, US residents are not authorized to participate to the subscription

    Is the ICO open to all countries?

    No. The token sale is not open to residents and citizens of the USA, P.R. of China, Canada, New Zealand, North Korea and any other country within the list of non-cooperative countries from the FATF.

    What if I contributed during pre-sale?

    If you contribute during the presale, you will receive a 30% bonus for your purchase, e.g. if you purchase 1,000,000 tokens, you will receive a total of 1,300,000 tokens.

    When does the private sale start?

    The private sale started in October 2018.

    When will I get the tokens?

    Subscribers will receive their RWD tokens no later than 3 calendar weeks after the end of the public sale.

    Do you have a prototype?

    We have much more than a prototype! We released the public version of our healthcare blockchain with a Dapp named PatientTruth on July 17th, 2018. We believe we are the first company in the world to release a public working healthcare blockchain product.

    What happened to unsold tokens?

    Unsold RWD tokens will be burned

    Is there an indicative roadmap for the next month / year(s)?

    Yes, we released Version 1 of our Embleema health blockchain in July 2018, and plan to release Version 2 in Q3 2019. More details on the roadmap are found in the Whiter Paper (« Implementation » section)

    There are many healthcare blockchains. How is Embleema different?

    Unlike any of our competitors vying for a space in the emerging Blockchain for healthcare space, we, at Embleema, have a live product with real patients as users. This provides key learnings and metrics to improve user experience, to fluidify data integration from different sources of medical records, or to understand how non-expert Blockchain users interact with the network.
    In addition, Embleema has validated with a first pilot with the Cystic Fibrosis community the support of patients for owning and receiving compensation for their data. In terms of clients, we have secured agreement with major pharmaceutical companies to pilot our Blockchain for RWE, including Pierre Fabre.
    We also have a solid understanding of the pharma regulatory environment, with existing and frequent interactions with health regulators. The leadership teams brings expertise from IQVIA / IMS – our CEO having led their technology solutions and business in France and Asia – and Withings / Nokia Health, a leader in IoT for health. Our advisers are life sciences experts or technology thought leaders from Harvard Medical School.

    Other healthcare blockchain ICOs have delivered disappointing returns, what should they have done differently?

    We are equally disappointed and worried by the fact that there so few real products in our area despite significant fundraising through ICOs. This throws a very bad image on the whole healthcare blockchain (and actually blockchain) industry. We highly recommend new players in this area to follow a traditional path of company development, which is to develop successfully a prototype, then an MVP, prove on the marketplace that the MVP is relevant and THEN, and ONLY THEN, launch an ICO to scale the business. This is the best way in our opinion to restore a damaged reputation for ICOs. We are helping new entrants through the Hyperledger Health Work Group by being a co-chair and leading the EMR sub workgroup, where we share learnings and accelerate our collective work on this area.

    Other healthcare blockchain ICOs have delivered disappointing returns, why will you be different?

    It is not surprising that other healthcare blockchain ICOs have yielded very disappointing returns, as they struggle to release a working product. Without a product on the market, you don’t have clients and revenue, and therefore the token asset is worthless, and the more delayed or unclear your date of release is, the trust the subscribers endowed at the ICO naturally erodes, hence the disappointment. We are very different as we started our business by releasing in July 2018 a public, fully functional and fully packaged product (Embleema health blockchain and Patienttruth Dapp), so we are beyond this phase of proving we can build a product, which indeed is a difficult thing the achieve.

    There were previous ICOs in the healthcare blockchain. How does yours differentiate?

    Our approach to ICO is the complete opposite than other healthcare blockchain ICOs. Other healthcare blockchain start-ups start their operations by launching an ICO, and then use the funds to develop a product. To our knowledge, none has released a public, fully-package product that any patient can register to and use. We did the opposite: we started our operations by developing a product (public, fully-packaged product that any patient can use), validated its relevance on the marketplace by signing and delivering contracts using our product, and then launch an ICO to scale our business. In that sense, we are using a traditional, proven, step-by-step funding model for succesfull growth and providing subscribers much stronger reassurance that our project will actually materialize.

    What is the difference betweent RWD and RWE tokens

    Our next version of the Embleema health blockchain as described in our white paper will use RWE tokens as a utility token to use the system and as a currency to buy and sell data. The RWE token will not be an ERC-20 token and will be issued at the genesis block of our blockchain planned for Q3 2019. For the ICO, we will therefore not be able to issue RWE tokens. Instead we will issue an ERC-20 token called RWD which will convert into RWE tokens on a 1-for-1 basis at the genesis block of our blockchain.

    Who are your ICO partners?

    This token sale is run under the projet de loi PACTE article 26 in France, we have partnered with top-rated players with significant experience in this matter: Fieldfisher, ECAN and WeStart

    Actualités

    Alexis Normand
    Alexis Normand
    Digital Health Evangelist, Embleema blockchain for healthcare consortium, former head of B2B Nokia Digital Health / Withings.
    Embleema closes Series A !
    Embleema is on a mission to…
    Lire l'article complet >
    Alexis Normand
    Alexis Normand
    Digital Health Evangelist, Embleema blockchain for healthcare consortium, former head of B2B Nokia Digital Health / Withings.
    La blockchain rend possible la propriété sur ses données personnelles
    Notre tribune dans Le Monde du 11 Janvier 2019 avec Robert Chu, Michèle Anahory et Olivier Spreux
    Lire l'article complet >

    Manifesto

    In 1951, Henrietta Lacks was admitted at John Hopkins hospital for cervical cancer. Her cells were extracted from her tumour and cultured. They became the HeLa immortal cell line, a source of invaluable medical data to present day, used to develop the first Polio Vaccine, cell cloning and to study HIV. Despite this outstanding contribution to research, Henrietta never gave her consent. She died in poverty with no compensation or acknowledgement until present day.

    We believe we have the right as patients to choose how our data is used for the common good. As digital health becomes the norm, this means changing the very organization of the Internet to reclaim control.

    Decentralization as Freedom

    The promise of the Internet has been broken. Decentralization of information was meant to promote ​free speech, democratize ​knowledge, abolish censorship, expand services remotely… But the Internet is now centralized by a handful of platforms. They monetize our data as their own asset to make us better consumers, not more enlightened or healthier citizens at the expense of working and innovating for the common good. Our data is nothing less than our digital assets in the virtual world and the same way we own and are free to dispose of our assets in the real-world, we should own and dispose of our digital assets.

    Our healthcare data is our most valuable digital asset: it can save our life in an emergency situation and provides critical decision-making information for the providers to offer us the best care. However, our records are held captive in protected silos for fear of being singled out, for fear of seeing our right to care violated. A wealth of digital data is lost to personalized medicine.

    Power to the Patients

    We want to become the steward of our health data, not having to rely on third parties to handle our most sensitive information. We have the right to break information silos, control where our data is stored, who has access to it, who we share it with. This power can dramatically affect how treatments are delivered, moving away from a top-down approach to an iterative process where we, patients, measure the effectiveness of more personalized treatments. This is a paradigm for medical research and change lives.

    In nodes we trust

    As third parties centralize our confidential data, unauthorized access becomes the norm. We, as patients, are kept out of the loop even in case of breaches. Decentralized ledgers let us enforce the security over our digital health assets, making tampering impossible, keeping track of violations in real-time, without no third party involved. Imagine we could still control our data even once it has been shared, removing access to enforce our privacy at any time.

    We believe in reclaiming our data with decentralized networks, to put patients at the center of care.

    Your Health Data, Your Property

    Hospitals or pharmacies monetize our health data to pharmaceutical and insurance companies for marketing or pharmacovigilance studies. Even though there are strong benefits for using our data, we are not taking part in the sale of our own data. Blockchain will let us enforce our property. Smart contracts will let us set the terms by which others access our digital assets. Instead of being robbed of our data, we will willingly get involved and be compensated for our contribution to the development of innovative treatments.

    Holding Blockchain to the Highest Standards

    Blockchain as a trust-generating technology is game-changing, destined to become the standard in industries that need trustworthy information without rent-seeking third parties. But its potential is shrouded by a wave of crypto-speculation that make the most solid projects look suspicious. To restore trust and allow news rights to come of age, we deliver real products with clear benefits, demonstrate financial transparency, and share our expertise to the healthcare ecosystem. We are working with regulators, health authorities, pharmaceutical companies, patient advocacy groups, care networks and providers to ensure patients, caregivers and researchers can reliably endorse the next generation of healthcare data.

    [contact-form-7 id="579" title="Investment Form"]

    Embleema ICO Public Sale Coming Soon